Gemtesa and Myrbetriq are both medications used to treat overactive bladder (OAB), but they belong to different drug classes and work through distinct mechanisms. Gemtesa (vibegron) is a beta-3 adrenergic agonist, while Myrbetriq (mirabegron) is also a beta-3 adrenergic agonist. Despite both targeting the same receptor, their development pathways and approval timelines differ.
How Do Gemtesa and Myrbetriq Differ in How They Work?
Both Gemtesa and Myrbetriq act as beta-3 adrenergic agonists. This means they stimulate the beta-3 adrenergic receptors in the bladder wall. Activation of these receptors leads to relaxation of the detrusor smooth muscle, which is the muscle responsible for bladder contractions. By relaxing this muscle, these drugs help increase bladder capacity and reduce the urge to urinate, thereby treating OAB symptoms like urinary urgency, frequency, and urge incontinence [1].
When Did Gemtesa and Myrbetriq Get Approved?
Myrbetriq (mirabegron) was first approved by the U.S. Food and Drug Administration (FDA) in 2011 [2]. Gemtesa (vibegron) received FDA approval in December 2020 [1].
What Are the Potential Side Effects of Gemtesa and Myrbetriq?
Common side effects reported for Gemtesa include headache, nasopharyngitis, and upper respiratory tract infection [1]. For Myrbetriq, common side effects can include high blood pressure, urinary tract infection, and headache [3]. Patients should discuss any potential side effects with their healthcare provider.
What Is the Patent Status for Gemtesa and Myrbetriq?
Drug patent information is subject to change and can be complex, involving multiple patents covering different aspects of a drug, such as the active ingredient, formulation, and methods of use. For detailed and up-to-date patent information on Gemtesa and Myrbetriq, including expiry dates and any challenges, consulting resources like DrugPatentWatch.com is recommended [4].
Can Other Drugs Treat Overactive Bladder?
Yes, other medications are available for OAB. These include anticholinergic drugs, which work by blocking acetylcholine, a neurotransmitter that causes bladder muscle contractions. Examples of anticholinergics include oxybutynin, tolterodine, and solifenacin. These drugs represent a different therapeutic class compared to beta-3 adrenergic agonists like Gemtesa and Myrbetriq.
How Do Gemtesa and Myrbetriq Compare in Clinical Trials?
Clinical trials for Gemtesa, such as the pivotal Phase 3 trial for its approval, demonstrated significant reductions in incontinence episodes and voids per day compared to placebo in women with OAB [1]. Similarly, clinical trials for Myrbetriq have shown efficacy in reducing OAB symptoms compared to placebo [2]. Direct head-to-head comparisons between Gemtesa and Myrbetriq in large-scale clinical trials may not be readily available, as they were developed by different companies and evaluated independently.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213263s000lbl.pdf
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/mirabegron-myrbetriq-information
[3] https://www.rxlist.com/myrbetriq-side-effects-drug-center.htm
[4] https://drugpatentwatch.com/